Ascletis Pharma Inc.

Our Focus

Cancer Lipid Metabolism

Cancer Molecular Therapies

Cancer Metabolism: Long History, Recent Breakthrough

Fatty Acid Synthase, A Promising Cancer Drug Target

Cancer Lipid Metabolism: Recent Breakthrough of FASN Inhibitors

• Investigator sponsored Phase 2 trial of TVB-2640 with Bevacizumab in Patients with First Relapse of High-Grade Astrocytoma

• 25 patients enrolled, both grade III and IV astrocytoma

• All patients received ASC40 (TVB-2640) (100mg/m2 PO QD) plus bevacizumab (10mg/kg IV D1,15) until treatment-related toxicity or progressive disease

• The overall response rate (ORR) for ASC40 (TVB-2640) plus bevacizumab of 65%

• Complete response (CR) of 20%

• Partial response (PR) of 45%

• Progression-free survival at six months (PFS6) for ASC40 (TVB-2640) plus bevacizumab was 47%

• Representing a statistically significant improvement in PFS6 over historical bevacizumab monotherapy (BELOB 16%, P=0.01)

• ASC40 (TVB-2640) in combination with bevacizumab was safe and well tolerated in such patient population

• Presented at European Society for Medical Oncology 2020

Oral Checkpoint Inhibitors

PD-L1 Small Molecule Inhibitors: Challenges and Opportunities

ASC63: Induce PD-L1 Dimerization and Sustained Internalization

Publications

Title	Venue	Type	Date
Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma	Clinical Cancer Research	Paper	04/2023
In vivo Efficacy Evaluation of ASC61, an Oral PD-L1 Inhibitor, in Two Tumor Mouse Models	The 2022 Annual Meeting of the American Association for Cancer Research (AACR)	Poster	3/2022
Efficacy of ASC60, an Oral Fatty Acid Synthase Inhibitor,in Two Tumor Mouse Models	The 2022 Annual Meeting of the American Association for Cancer Research (AACR)	Poster	3/2022
First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640	The 2017 American Association for Cancer Research (AACR) Annual Meeting	Poster	04/2017